HRS-7085 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Ulcerative Colitis (ACG 2026) - P2 | "Overall, 30 patients were randomized and all received at least one dose of treatment. The baseline demographics and clinical characteristics were generally balanced across groups. At Week 8, in the HRS-7085 10 mg and 20 mg BID titration groups, the placebo-corrected clinical remission rates were 54.5% and 66.7%, and the clinical response rates were 40.9% and 38.9%, respectively."

Clinical • P2 data • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • TNFA

HRS-7085-201: A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting | N=30 ➔ 66 | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Atridia Pty Ltd. | Recruiting ➔ Completed | N=42 ➔ 16

Enrollment change • Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Atridia Pty Ltd.

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease